T1	Treatment 113 147	omega-3 fatty acids and sertraline
T2	Treatment 924 1056	with three parallel groups involving omega-3 fatty acid supplementation or sertraline hydrochloride, compared with matching placebo.
T3	Treatment 1538 1689	At three months, subjects will undergo structural neuroimaging to assess whether treatment effects on depressive symptoms correlate with brain changes.
